Pinto Beans & Penny Stocks 2020 (BEAN)

[3331]

BIEL: 911 "news pending" market maker trade a little and multiple 100 "I need shares" market maker trades Friday!

[Mrspencers]

$CBLO | C2 BLOCKCHAIN: Cardano (ADA) Acquisition Signals Long-Term Vision

C2 Blockchain Inc. ($CBLO) is in the process of acquiring 1,000,000 ADA — a strategic move aimed at strengthening its position in the blockchain space.

• ADA Focus: Cardano’s energy-efficient architecture and growing DeFi ecosystem align with CBLO’s commitment to scalable, responsible tech.
• Digital Asset Strategy: This acquisition forms the backbone of CBLO’s treasury approach, mirroring institutional tactics seen in early crypto adoption.
• Ecosystem Expansion: Alongside mining and AI fintech development, ADA becomes a key pillar in CBLO’s multi-sector blockchain footprint.
• Transparency & Execution: Publicly reported, actively building — a methodical approach to blockchain operations.

This isn’t hype — it’s a structural commitment to quality assets.

[gladeshawk]

LTUM>>>>Volume up and price moving up. HAWK

[ProfitScout]

$IVDN Feature: 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs

$IVDN Innovative Designs, Inc. (Stock Symbol: IVDN) Board Member has Ties to Industry Leaders Including D.R. Horton $DHI, Ryan Homes $NVR and More / Super Small Share Structure with Only 38 Million OS / 16 Million Float
LINK:
https://www.prlog.org/13078241-150-increase-in-fiscal-q2-sales-vs-previous-year-to-750000-continuous-record-quarters-profitability-for-homebuilding-product-innovative-designs.html

From the article:

Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating, Water Vapor, Air & Wind Barrier and Other Important Advantages.

Second Quarter Revenue Projection of $750,000 (150% Increase Over Q2 of Previous Year).

First Half of 2025 Already Approximately Equals All of 2024 Revenue Total.

Fiscal First Quarter Results Deliver Over a 720% Increase, Largest Percentage Revenue Growth in Company History.

Profitability Reached for First Time at Fiscal 2024 Year-End on Almost 300% Revenue Increase vs. Previous Year.

New Government Building Codes Require Continuous Insulation with Higher Performance. IVDN Meets or Exceeds These Standards Where Many Competitors Now Do Not.

Increased Order Fulfilment Capabilities with Plans for Further Enhancement to Handle Strongly Increasing Demand.

[Golden Cross]

$LITM Snow Lake is actively pursuing acquisitions in the nuclear energy sector to expand its project pipeline! Bet we hear more news soon... Adding here when I can...

#Uranium #Nuclear #cleanenergy #mining

[Golden Cross]

$LITM U.S. Administration's Nuclear Executive Orders Help Fast Track Snow Lake's Pine Ridge Uranium Project Development Timelines
https://www.newsfilecorp.com/release/253433/U.S.-Administrations-Nuclear-Executive-Orders

[gladeshawk]

LTUM, QS related to new solid state EV battery. FYI. HAWK

https://www.msn.com/en-us/news/technology/startup-embarks-on-quest-to-develop-next-gen-batteries-that-could-revolutionize-electric-vehicles-we-can-be-competitive/ar-AA1Fub49?ocid=msedgntp&pc=DCTS&cvid=f28f063f66894d86b7bc321614cc2d48&ei=34

[3331]

BIEL - RecoveryRx now available to all veterans at all VA's!

[linkvest]

ASII.... You don't own this stock? You should......... https://www.otcmarkets.com/stock/IQST/news/IQST---IQSTEL-Sparks-Rapid-Global-Fintech-Expansion-with-GlobeTopper-Acquisition----Fast-Tracking-1-Billion-Growth-Plan?e&id=3251837

[2times2]

MSRM + Mycolab INC., Market cap ridiculously low, SS tiny and unchanged, Independent directors, Products rolled out, first (small) revenue reported, management certification filed to list on OTCID come July

Authorized Shares 400,000,000 05/27/2025
Outstanding Shares 39,435,760 05/27/2025
Restricted 26,839,148 05/27/2025
Unrestricted 12,596,612 05/27/2025
https://www.otcmarkets.com/stock/MSRM/disclosure

https://www.mushroomsinc.com/
https://mycolabx.com/

[3331]

BIEL - HOT NEW PRODUCT, RAVE REVIEWS!
https://mcintyre-canine-rehabilitation.mykaja...pwaQWVSUHw

[3331]

BIEL + DR OZ = $$$
https://www.facebook.com/ActiPatch/videos/423907841012124/?mibextid=rS40aB7S9Ucbxw6v

[Zardiw]

So I was talking to my friend and good stocks came up.

I told him about $OODH oil/gas co, and how they got zero debt.

He said he'd never heard of that......and I haven't either fwiw:



Z

[Golden Cross]

$OODH Market Cap insanely low here! $10 Million in Rev's last year and growing monthly!

[3331]

BIEL - VA HUGE
Flagship product RecoveryRX now available to all veterans at all VA's!
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."

[Zardiw]

$OODH News: More Royalty Assets Acquired!!:

Tom Lull, CEO: "We now have 3-2 ½ mile horizontal wells drilled on our royalty acreage in the Scoop Stack of Oklahoma. We anticipate revenue checks from 2 of these horizontal wells in Kingfisher County Oklahoma will start to pay in late May 2025. We anticipate revenue from the 2 ½ mile horizontal well recently drilled in Grady County Oklahoma will pay in late June 2025. Orion has more than 1,000 royalty acres in the Scoop Stack area surrounding Oklahoma City." Commented Tom Lull, CEO of Orion. Orion's revenues exceeded $20,000 in the month of April 2025 from our royalties and non op working interest outside of Oklahoma. Orion now owns 53,160 mineral acres in the Bakken, Permian Basin, Piceance Basin, Arkoma Basin, Eagle Ford, and Scoop Stack of Oklahoma. "

https://www.accessnewswire.com/newsroom/en/orion-announces-oklahoma-scoop-stack-royalty-acquisitions-1030938

Z

[Golden Cross]

$OODH Undervalued Oil & Gas Play

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

PALM BEACH, Fla., May 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will be presenting a Company update at the upcoming Wall Street Conference, taking place on May 21, 2025 in Palm Beach, FL. NRx is one of six companies invited to present.

The Wall Street Conference is expected to host over 1,000 attendees who are reported to represent over $1T in investment capital. Wall Street Conference Home

NRx will be discussing recent progress towards FDA approval of NRX-100 (preservative-free ketamine) and upcoming acquisitions of HOPE clinics providing state-of-the-art care for suicidal depression, PTSD, and related disorders.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (preservative free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including, without limitation, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, NRX-100 not being approved by the United States Food and Drug Administration, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Matthew Duffy

Brian Korb

Co-CEO, Hope Therapeutics, Inc.

Managing Partner, ASTR Partners

Chief Business Officer, NRx Pharmaceuticals, Inc.

[phone]

[e-mail]

[e-mail]

https://c212.net/c/img/favicon.png?sn=CL91815&sd=2025-05-21 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-selected-to-present-at-the-wall-street-conference-on-may-21-2025-in-palm-beach-florida-302461059.html

SOURCE NRx Pharmaceuticals, Inc.

[3331]

BIEL's RecoveryRx HUGE in plastic surgery.
Steven Ray Garcia Owner/Operator-Sandlot Medical: "This is a great product. I work with a couple top Plastic Surgeons in Scottsdale, and Recovery RX is part of their breast augmentation recovery protocol."

[Golden Cross]

$NGCG .0011 Easy Multi-Bagger From Here!

[toastturtle]

$ISPNF Low Float Gold Play. New US and German Listings. Only 18M shares out. Just announced German Marketing Group Plutus who have good results form many companies in the JR market. Drill program expected in roughly 6 weeks. Airborne surveys being completed now. Trading below $0.15 currently but shouldn't be there long. Feel like it could double by the time the work starts. Not a recommendation. Do some DD.

[3331]

BIEL: 5 STARS!
Green Light ON...Pain is Gone!
Reviewed in the United States on May 5, 2025
I've been using this for a few years now and works great on my lower back and knee pain. I put one on my lower back before golf each week and zero pain. Highly recommend and don't leave home without it.

[Mermelstein]

INBP - $0.33. 2 cent EPS reported. Added some more today in the low .30s. Can't really find anything I like better than this at the moment.
~$10m market cap
$3m in net cash
$50m+ revenue
$0.02 EPS last Q, fully taxed
Around 3x ttm EV/EBITDA
Tangible Book value 100% higher
Billionaire owners of Celsius energy drinks own almost 50% of the stock. Think they will just buy out the other half of the company eventually.

[ProfitScout]

$CVKD: Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

PONTE VEDRA, Fla.--(BUSINESS WIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.

Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway.

“We are pleased with the important progress we have made with the supply chain and cGMP manufacturing process for tecafarin,” said Quang X. Pham, Chairman & CEO. “This is a key milestone as we support our clinical development strategy and tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation.”

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects.

Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/ and connect with us on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation and pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation, the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20250515408603r1&sid=acqr8&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515408603/en/

Corporate and Investor Relations
Paul Sagan
LaVoieHealthScience
[phone]
[e-mail]

Media
Andrew Korda
LaVoieHealthScience
[phone]
[e-mail]

Source: Cadrenal Therapeutics, Inc.

[BGCapital]

ADHC share holder update on X today

$ADHC Shareholder update out just now!

They have a lot going on right now. Keep an eye out for PRs

Also they received a favorable review by the FDA on their Breakthrough Device application a few weeks ago. Glucoguard coming closer to breakthrough device designation by the FDA… https://t.co/X8uoaU44LW

— Stock Picks NYC (@StockPicksNYC) May 14, 2025

Keep an eye out for multiple PRs on the way

[BGCapital]

ADHC share holder update on X today

$ADHC Shareholder update out just now!

They have a lot going on right now. Keep an eye out for PRs

Also they received a favorable review by the FDA on their Breakthrough Device application a few weeks ago. Glucoguard coming closer to breakthrough device designation by the FDA… https://t.co/X8uoaU44LW

— Stock Picks NYC (@StockPicksNYC) May 14, 2025

Keep an eye out for multiple PRs on the way

[Golden Cross]

$NGCG brand new 000 play here!

[3331]

BIEL: HUGE HIT IN SOUTH AFRICA!
https://beprepared365.co.za/products/2/actipatch

[Golden Cross]

$LITM Snow Lake’s strategic focus on uranium — a critical resource in the clean energy transition.
https://allcapresearch.com/f/snow-lake-energy-litm-expands-global-uranium-push

[3331]

BIEL - VA HUGE, ÷200%
https://veteranrecovery.org/
Flagship product RecoveryRX now available to all veterans at all VA's!
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584

[Golden Cross]

$NGCG New 000 Play! Shell Sold_New Owner_Very Early Here!

[TheFinalCD]

https://www.youtube.com/shorts/yJ2LOVU-23Q

🙏✝️ for you and your family, and what a Blessing to see your daughter

my mother in law is battling stage 4 cancer😕

Cancer is an incredible force

but not an unbeatable one

Peace & Cheese brotherrrrr

[TheFinalCD]

https://www.youtube.com/shorts/yJ2LOVU-23Q

[gladeshawk]

LTUM >>> Recent increase in volume and pps. This could be the reason. Lithium prices to see increases soon. Just a FYI. HAWK

https://finance.yahoo.com/news/lithium-corporation-commences-2025-field-102000340.html

[Golden Cross]

$LITM Looking for a nice Post-RS move! $20 Million Cash on hand! Think we can see a 50-100% move soon!

Could hear news out of the Critical Minerals Conference today! Loading up... Trading at about cash value here!

[gladeshawk]

LTUM>>>> Pure penny play. Executive Order from WH put out to help in increase U.S. rare earths production. Bigger move UP is coming, imho. At a minimum keep on your watch lists. Just a FYI. HAWK

[3331]

BIEL - Actipatch/Recovery Wave huge in the UK, covered by the National Health Service (NHS)!

NEW ZEALAND SALES LAUNCHED!
https://www.actipatch.nz/

[TheFinalCD]

https://www.youtube.com/shorts/BDwjToHoOLo

[linkvest]

RDAR... NEWS NEWS NEWS Telvantis, Releases the Interview From the Floor of the NYSE on YouTube https://finance.yahoo.com/news/raadr-inc-doing-business-telvantis-123000456.html

[linkvest]

RDAR... RDAR should be in your portfolio today..... The NYSE floor interview date is set for April 23, 2025. The release of the interview to the public will be on April 30, 2025.
The selection of topics will include the following:
Acquisitions and corporate expansion plans
PCAOB audit updates
Revenues
“Both shareholders and the Company have gone through some amazing transformations over the past few months as we completed Phase 1 and moved on to Phase 2 of our 2025 growth strategy. To be selected for an interview on the floor of the NYSE is an honor and testament to what we are building here at Telvantis,” commented Daniel Gilcher, CFO of Telvantis, who will be representing the Company on the floor of the NYSE.

[BGCapital]

ADHC woah!! Received favorable FDA review see today news

$ADHC pretty big news today! Received Favorable FDA Review

“Virtually all of the requirements for Breakthrough Designation were acknowledged by the FDA to have been fulfilled in the GlucoGuard® application

Specifically, the FDA acknowledged that:

•The GlucoGuard® device… https://t.co/nwTCymEmXL pic.twitter.com/EJddxT0ccr

— Stock Picks NYC (@StockPicksNYC) April 29, 2025

The market cap is only $1M so it can actually run up pretty high from here

[Magnum7419]

$AHRO :)

[BGCapital]

RDAR heavy volume lately, new DD here

$RDAR DD (Part 1)

•$5M market cap

•$32M revenue across Feb-March

•$62M in Assets (10-K)

•Audit underway

•Big name clients including AT&T $T, Verizon $VZ

•Acquisitions, evaluating targets

•Share buyback

•NYSE Floor interview 4/30

•Multiple analyst reports issued… https://t.co/gY5Q2txkW6 pic.twitter.com/8wgRFsYfcm

— Stock Picks NYC (@StockPicksNYC) April 28, 2025

[ProfitScout]

$RMXI News: Reticulate Micro, Inc. Completes Acquisition of Remaining RMX Industries Inc. Shares, Consolidates Operations, and Expands Leadership Team

ST. LOUIS, April 23, 2025 /PRNewswire/ -- Reticulate Micro, Inc. ("RMX" or the "Company") (OTCQB: RMXI), a software products company specializing in advanced video compression technology, announced today that it has acquired the remaining shares of RMX Industries Inc., the Company's 50/50 joint venture company with K2 Endeavor DMCC, through a stock exchange transaction, making it a wholly-owned subsidiary. The move consolidates operations and aligns resources to accelerate commercial business opportunities across key sectors.

As part of this strategic consolidation, RMX is also pleased to announce important changes to its governance and management teams:

M. Steven Kirchof has been appointed as an independent member of the Company's board of directors. Mr. Kirchof has over 20 years of experience building entrepreneurial companies and driving innovation in healthcare technology. Mr. Kirchof is the CEO of CureGrail, Inc., a healthcare technology company engaging and empowering patients to own and manage their disease, and founder and CEO of RxPath, LLC (originally OneOncology), a healthcare transaction company. Mr. Kirchof previously co-founded Matrix Oncology (acquired by Express Scripts) and served in executive, sales management, marketing, and strategy leadership positions at iKnowMed, Inc., MedStat Group, and IBM Healthcare. A Harvard-trained executive and summa cum laude graduate from Western Carolina University, Mr. Kirchof remains active in conservation, faith-based leadership, and community development initiatives across Florida and Texas.

Karl Kit has been appointed as the Company's Chief Executive Officer, President and as a member of the board of directors. Mr. Kit is a seasoned entrepreneur with over 40 years of international business experience across advertising, communications, mobile data services, and financial technology. Mr. Kit previously headed K2 Endeavor DMCC, a UAE-based strategic investment group. Throughout his career, Mr. Kit has lived and worked across the globe, including in South Africa, Europe, and the United States collaborating with industry leading companies to implement global strategies. His broad international leadership experience will be instrumental as RMX continues its global expansion.

Andrew Sheppard has been appointed as the Company's President of RMX Government. Mr. Sheppard will lead RMX's efforts in the defense and government sectors, focusing on deploying its cutting-edge video and data compression technologies to meet the mission-critical needs of military and public safety customers. Mr. Sheppard previously served as the Company's Chief Executive Officer and President.

Maxwell Kit has been appointed as the Company's Chief Marketing Officer. Mr. Kit has extensive experience in global brand strategy, digital engagement, and go-to-market execution. As CMO, he will lead RMX's marketing and communications efforts, refine the Company's brand identity, and expand its market visibility. Mr. Kit will oversee the launch of integrated campaigns that highlight the transformative power of RMX's proprietary compression technology across defense, AI, telecommunications, and enterprise sectors. His leadership will be critical as RMX scales operations and forges new strategic partnerships worldwide.

About RMX (Reticulate Micro, Inc.)
RMX (Reticulate Micro, Inc.) (OTCQB: RMXI) is a technology company specializing in advanced data compression and video optimization. Leveraging proprietary, field-validated technology that has demonstrated exceptional performance in the most demanding environments, RMX is aiming to transform the way organizations capture, transmit, store, and share visual data. Originally developed for mission-critical military applications, RMX's platform reduces video bandwidth, storage needs, and power consumption by up to 50%—all without compromising quality or functionality across any network or hardware infrastructure. As data becomes a foundational asset across defense, AI, cloud, and enterprise ecosystems, RMX is positioned to lead the next generation of intelligent, efficient data compression solutions in a rapidly digitizing world.

Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements that are subject to various risks and uncertainties. In addition, our representatives or we may make forward-looking statements orally or in writing from time to time. We base these forward-looking statements on our expectations and projections about future events, which we derive from the available information. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical facts, particularly those that use terminology such as "intends," "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, including the risks described in the risk factors section of the reports and other documents that we file with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update any forward-looking statements except as may be required by law.

Important Notice Regarding Our Regulation A Offering
An offering statement regarding our offering of units consisting of one share of class A common stock and a warrant to purchase one share of class A common stock has been filed with the SEC. The SEC has qualified that offering statement, which means that Reticulate Micro may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. You may obtain a copy of the offering circular that is part of that offering statement through this link.

Investing in a public offering like our Regulation A offering is subject to unique risks, tolerance for volatility, and potential loss of your investment, that investors should be aware of prior to making an investment decision. Please carefully review the risk factors contained in the offering circular for this offering. For more information about Regulation A offerings, including the unique risks associated with these types of offerings, please click on the SEC's Investor Alert.

Neither this document nor any of its content constitutes an offer to sell, solicitation of an offer to buy or a recommendation for any security by Reticulate Micro or any third party. The content of this document is provided for general information purposes only and is not intended to solicit the purchase of securities or to be used as investment, legal or tax advice. A securities offering by Reticulate Micro is only being made pursuant to the offering circular described above. The content of this document is qualified in its entirety by such offering circular. Prospective investors are urged to consult with their own investment, legal and tax advisors prior to making any investment in Reticulate Micro.

Contact:
Media:
RMX (Reticulate Micro, Inc.) Media Relations
[e-mail]

Investor Relations:
RMX (Reticulate Micro, Inc.) Investor Relations
[e-mail]

[BGCapital]

Watch these TWOH RDAR VGTL RCHO BNCM AHRO

[linkvest]

RDAR... NEWS NEWS.... this stock is a must buy still at .0007....
EQS-News: Raadr Inc., Doing Business as Telvantis, Selected for an Interview on the Floor of the NYSE Press Release | 04/23/2025

EQS-News: Raadr Inc., Doing Business as Telvantis, Accelerates With $32M+ in Revenue Across February and March; Business Plan Relaunch Gaining Momentum Press Release | 04/21/2025

EQS-News: Raadr, Doing Business as Telvantis, Transitions From Restructuring to Execution; Launches Phase 2 of Growth PlanPress Release | 04/10/2025

EQS-News: Raadr Inc., Doing Business as Telvantis, Completes Final Stage of Legacy Debt Remediation, Paving the Way for New Growth Phase Press Release | 04/01/2025

[ProfitScout]

$RDAR News: Raadr Inc., Doing Business as Telvantis, Accelerates With $32M+ in Revenue Across February and March; Business Plan Relaunch Gaining Momentum

NEW YORK - April 21, 2025 (NEWMEDIAWIRE) - Raadr Inc., doing business as Telvantis (OTC: RDAR) ("Telvantis" or the "Company"), a U.S.-based technology-driven telecommunications and enterprise solutions provider, today announced approximately $32 million in revenue across February and March 2025, confirming strong execution of its business relaunch and growth strategy.

With $12.5 million in February and $19.6 million in March, the companys revenue trajectory continues to accelerate, validating Telvantiss position as an emerging force in the telecom technology space. This milestone comes on the heels of Telvantis completing its legacy debt remediation and officially entering the next phase of scalable operations.

This isnt hypothetical. This is verified revenue, and it proves our platform is delivering real results at scale, said Daniel Contreras, CEO of Telvantis. Weve spent the last few months quietly rebuilding our foundation, and now were turning up the volume. Were executing. Were accelerating. And were just getting started.

The Companys Gross Margin totaled approximately $1 million over these two months and generated a slight positive operating profit before financing costs. The Companys complete financial statements will be included in the Companys quarterly report, which is due May 15, 2025.

This is a first important step towards the delivery of our ambitious plan, and there is more work to be done to drive profitability over the rest of the year. We will stay on course and focus on both gross profit margin improvement and cost savings, added Contreras.

Note that all mentioned numbers are unaudited.

Key Revenue Drivers

Enterprise Messaging (CPaaS): Telvantis powers secure A2P messaging and verification services across fintech, healthcare, and ecommerce clients worldwide.
Telecom Carrier Optimization: Revenue from high-volume routing and traffic management across Telvantis's 300+ global carrier relationships.
Global Expansion: Strong international delivery capacity and new B2B relationships fueled growth across both months.
A New Phase of Scalable Growth

These numbers signal that Telvantiss restructuring and transition efforts in 2024 have culminated in a functional, revenue-generating and profitable model that is now scaling quickly.

February and March prove our plan is working, added Daniel Gilcher, CFO of Telvantis. Were entering Q2 with stronger systems, growing relationships, and increasing market traction. Now that weve addressed our past obligations, our focus is squarely on intelligent expansion and shareholder value.

What Comes Next

Q1 2025 Revenue Summary: A full report on first-quarter performance will follow shortly.
Acquisition Strategy: With the foundation in place, Telvantis is now actively evaluating accretive acquisition targets to accelerate market share and service offerings.
Uplisting & Transparency: Audits are underway as the company continues to prepare for potential uplisting and enhanced corporate governance.
About Telvantis

Raadr, Inc., now doing business as Telvantis (OTC: RDAR), is a U.S.-based telecommunications company delivering advanced solutions to operators, enterprises, and network providers worldwide. Through its recent acquisitions of operations in the U.S. and Ireland, Telvantis has strategically expanded its portfolio to encompass cutting-edge 5G technologies, cloud-based communications platforms, and enterprise-grade services. This expansion, combined with a forward-thinking approach, positions Telvantis for accelerated growth and market leadership in the evolving telecommunications landscape.

Forward-looking statements

This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the Company's current expectations regarding future events and are based on management's beliefs and assumptions. Actual results could differ materially from those projected due to various factors, including market conditions, competition, and the successful integration of acquired operations. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Relations Contact

Raadr Inc. (doing business as Telvantis)
1680 Michigan Avenue, Suite 700
Miami Beach, FL 33139
Email: [e-mail]
Website: www.telvantis.com
Twitter/X: @Telvantis
LinkedIn: Telvantis

View the original release on www.newmediawire.com

News Source: Telvantis Inc.

[BGCapital]

Heads up on RHCO $5.7M in revenue last quarter and net profitable. Only 24M shares held at DTC. New play I’m going to be posting a lot of DD on them

$RHCO News out today! Going to post some DD on this gem tomorrow

•$5.7M in revenue last quarter Q4
•Net profitable
•$12.9M in assets
•No convertible notes

•Small float, 24M held at DTC pic.twitter.com/gGumzSuWIV

— Stock Picks NYC (@StockPicksNYC) April 21, 2025

[3331]

BIEL + DR. OZ + RFK = $$$
BIOELECTRONICS FLAGSHIP PRODUCT - ACTIPATCH - ON DR. OZ:
Dr. Oz devoted a whole program to explaining PEMF Pulsed ElectroMagnetic Field technology - with audience members wearing Actipatches (BIEL's flagship product) - saying it is changing the practice of medicine.
https://www.facebook.com/share/v/18NzZcGQVm

[Golden Cross]

💲$TWOH .0029 Next_Monster_RM_Play! 10,000%_Possible!